| | | | | |

Ofev Fails to Boost Mesothelioma Survival in New Study

ByAlex Strauss

In the quest to develop new, more effective first-line treatments for malignant pleural mesothelioma, it now looks like Ofev (nintedanib) is out of the running.

Phase III results of the LUME-Meso mesothelioma trial are in and they contain some disappointing news for mesothelioma patients and for the drug’s developer, Boehringer Ingelheim.

The news is especially disappointing since the results of the Phase II portion of the trial, released last year, looked promising. At that time, researchers reported a survival gain of more than 5 months among the Ofev-treated mesothelioma patients and progression-free survival of four months.

But further research did not support those results, as investigators announced to the world’s lung cancer experts at the IASLC 19th World Lung Cancer Conference last month.

“We are disappointed that the encouraging efficacy signal observed for nintedanib in Phase II was not confirmed in a larger Phase III trial, as there still remains a big gap in treatment options for patients with malignant pleural mesothelioma,” said Dr. Victoria Zazulina, Global Head of Solid Tumor Oncology at Boehringer Ingelheim.

Zazulina said results from the failed trial could still help guide future mesothelioma research.

Why There Were High Hopes for Ofev in Mesothelioma Treatment

Nintedanib is an oral drug designed to block a protein called VEGF which stimulates the formation of the blood vessels that mesothelioma tumors need to live and grow.

Evidence suggests that VEGF may also play a role in suppressing the immune system’s ability to fight cancers like mesothelioma and research has found that mesothelioma patients who have higher serum levels of of the protein have a lower chance of survival.

LUME-Meso was a phase II/III randomized double-blind trial aimed at assessing the safety and effectiveness of nintedanib along with pemetrexed (Alimta) and cisplatin as a first-line mesothelioma treatment.

It was thought that nintedanib would counter the effects of VEGF in mesothelioma patients and compound the effects of their chemotherapy.

Other VEGF Inhibitors Still in the Running for Mesothelioma

Although Ofev failed to meet expectations for mesothelioma researchers, a number of other VEGF-inhibitors are still being studied and, in some cases, used in mesothelioma treatment.

The VEGF inhibitor bevacizumab (Avastin) in combination with pemetrexed/cisplatin chemotherapy has been adopted as the standard of care for first-line mesothelioma treatment in France.

The addition of Avastin to standard mesothelioma care came after the 2016 French-led mesothelioma avastin cisplatin pemetrexed study (MAPS) showed that the VEGF inhibitor improved mesothelioma survival by 23 percent.

In the US, the National Comprehensive Cancer Network guidelines have also included this three-drug combination as an option for standard first-line mesothelioma treatment since 2016.

VEGF blockers sorafenib (Nexavar) and cediranib (Recentin) have also been shown to have an impact on the effectiveness of mesothelioma chemotherapy.

Source:

“Results of LUME-Meso trial in malignant pleural mesothelioma presented at the 19th World Conference on Lung Cancer (WCLC 2018)”, September 25, 2018, Boehringer Ingelheim new release, https://www.boehringer-ingelheim.us/press-release/results-lume-meso-trial-malignant-pleural-mesothelioma-presented-19th-world-conference

 

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…